SAFE-BioPharma Association has created SBP Digital Trust Consulting, a resource of internationally recognized identity and access management (IAM) policy and technical experts for life science and healthcare companies seeking to develop improved cyber security strategies.
"Identity and access management are critical to effective cyber security," said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association. "Any biopharmaceutical or healthcare organization seeking to evaluate or improve its cybersecurity through improved identity and access management strategies would be prudent to consider the services of the experts participating in SBP Digital Trust Consulting."
SAFE-BioPharma is the nonprofit coalition responsible for the on-going development and implementation of the global SAFE-BioPharma digital identity and signature standard.
Personnel available through SBP Digital Trust Consulting work with policy, technical, security and compliance staffs to assess and develop IAM strategies, build IAM system requirements, develop required certificate and credential policies and practice statements, and to assist in required procurement actions. Unaffiliated with vendors or other commercial suppliers, they are committed to objectivity in their recommendations.
SBP Digital Trust Consulting also provides expert counseling on identity and access management considerations in the areas of healthcare and biopharmaceutical business process improvement, regulatory compliance, and communications outreach.
Specific capabilities include:
SAFE-BioPharma also has access to a full range of other services through contractual relationships with several leading consulting firms. SAFE-BioPharma pharmaceutical members include AbbVie, Astellas, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Merck, Pfizer and Sanofi, among others.